Phase II Study of VS-6063, A Focal Adhesion Kinase (FAK) Inhibitor, in Patients With KRAS Mutant Non-Small Cell Lung Cancer
Phase of Trial: Phase II
Latest Information Update: 01 Feb 2017
At a glance
- Drugs Defactinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Verastem
- 24 Jan 2017 Status changed from active, no longer recruiting to completed.
- 31 Mar 2016 Planned End Date changed from 1 Feb 2016 to 1 May 2016 as reported by ClinicalTrials.gov record.
- 16 Dec 2015 Planned End Date changed from 1 Nov 2015 to 1 Feb 2016 as reported by ClinicalTrials.gov.